Brokers Offer Predictions for CLDX FY2025 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Celldex Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earnings of ($3.61) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $67.00 price objective on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

CLDX has been the topic of a number of other research reports. The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Citigroup began coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective on the stock. Finally, Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $62.25.

Celldex Therapeutics Stock Performance

CLDX opened at $24.41 on Wednesday. The stock has a market capitalization of $1.62 billion, a PE ratio of -9.50 and a beta of 1.62. Celldex Therapeutics has a one year low of $22.17 and a one year high of $53.18. The business’s 50 day moving average price is $25.65 and its 200 day moving average price is $31.63.

Insiders Place Their Bets

In related news, CEO Anthony S. Marucci purchased 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Celldex Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. KBC Group NV raised its position in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,647 shares during the last quarter. SG Americas Securities LLC lifted its position in Celldex Therapeutics by 24.4% during the 4th quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company’s stock worth $639,000 after acquiring an additional 4,967 shares in the last quarter. Mirador Capital Partners LP increased its holdings in shares of Celldex Therapeutics by 2.9% in the 4th quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company’s stock valued at $3,020,000 after acquiring an additional 3,345 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in Celldex Therapeutics by 5.1% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after buying an additional 2,070 shares during the period. Finally, Geode Capital Management LLC raised its stake in Celldex Therapeutics by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock valued at $52,372,000 after acquiring an additional 6,557 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.